Royal DSM signs XD technology licensing deal with Amgen
XD technology is an intensified cell culture process with typical XD titer improvement of 8-10 times and is applicable for multiple biological products such as proteins, fusion proteins
Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.
According to the deal, PharmAthene will use the technology in the production of recombinant butyrylcholinesterase (rBChE) bioscavenger. rBChE absorbs toxins including organophosphorous compounds and certain pesticides with the